Mankind Pharma Partners with Lepra Society to Screen 80,000 for Leprosy

Mankind Pharma, an Indian pharmaceutical company, has announced a strategic partnership with the Lepra Society to launch a comprehensive campaign to eradicate, raise awareness, and cure leprosy. As a CSR initiative, the company is committed to making a significant impact in leprosy-affected areas and, as part of this effort, has established five Comprehensive Disability Care Centers (CDCC) in different locations.

CDCCs have been deployed in selected high-impact areas, including the NTR district in Andhra Pradesh, Guru Govind Hospital in Delhi, Chandarpur Hospital in Maharashtra, and Odisha Community Health Center in Koraput and Nirmal districts. In Telangana. The center operates year round and deals with various issues related to leprosy and influenza. The company aims to work closely with the Leprosy Society to provide essential treatment and raise awareness through these centers.

Sheetal Arora, CEO of Mankind Pharma, said, "Our partnership with the Leprosy Society is a step forward in our mission to eradicate leprosy and raise awareness. CDCCs in key regions are important in treating and supporting people affected by leprosy. Targeted communities are expected to benefit from the new leprosy program."

Mankind Pharma will do important work to fight leprosy and its socioeconomic effects. More than 80,000 people will receive comprehensive tests and a program of comprehensive intelligence designed to educate and inform the community.

The plan also aims to serve more than 6,000 patients through disease and disability management programs, demonstrating its commitment to holistic care. More than ten reconstructive surgeries are performed to save the lives of those affected. Public support will also be extended to more than 400 families to address various community issues.